---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-134464"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:35:47.818463+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q3 revenue $56.7M (+407% YoY); net loss $0.18/share; 582 clinical trials supported

## Summary
- Total revenue $56.7M for Q3 2021, up 407% YoY; organic growth 38%.
- Net loss attributable to common stockholders $8.5M ($0.18 per share), vs $11.4M ($0.29) in Q3 2020.
- Adjusted EBITDA $5.6M in Q3 2021, vs -$0.7M in Q3 2020; gross margin 41.5% vs 54.2%.
- Supported 582 clinical trials (up from 561 in Q2 2021) and eight commercial therapies in regenerative medicine.
- Cash and short-term investments $349.5M as of Sep 30, 2021, up from $93.3M on Dec 31, 2020.

## SEC filing metadata
- accession: 0001104659-21-134464
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465921134464/0001104659-21-134464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465921134464/tm2126235d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-134464
- JSON: https://secwatch.observer/filing/0001104659-21-134464.json
- Plain text: https://secwatch.observer/filing/0001104659-21-134464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.